Business Description
NRX Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US6294441000
Share Class Description:
STU:B1Q: Ordinary SharesDescription
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | -4.22 | |||||
| Debt-to-Equity | -0.35 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 36 | |||||
| 3-Year EPS without NRI Growth Rate | 35.6 | |||||
| 3-Year FCF Growth Rate | -62.8 | |||||
| 3-Year Book Growth Rate | 46.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.79 | |||||
| 9-Day RSI | 55.81 | |||||
| 14-Day RSI | 54.69 | |||||
| 6-1 Month Momentum % | 25.37 | |||||
| 12-1 Month Momentum % | -40.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.2 | |||||
| Quick Ratio | 0.2 | |||||
| Cash Ratio | 0.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.9 | |||||
| Shareholder Yield % | -11.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -300.24 | |||||
| ROIC % | -203.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.11 | |||||
| EV-to-Forward-EBIT | -1.78 | |||||
| EV-to-EBITDA | -1.11 | |||||
| EV-to-Forward-Revenue | 5.41 | |||||
| EV-to-FCF | -1.89 | |||||
| Earnings Yield (Greenblatt) % | -90.09 | |||||
| FCF Yield % | -61.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NRX Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.458 | ||
| Beta | 0 | ||
| Volatility % | 108.29 | ||
| 14-Day RSI | 54.69 | ||
| 14-Day ATR (€) | 0.328975 | ||
| 20-Day SMA (€) | 4.807 | ||
| 12-1 Month Momentum % | -40.53 | ||
| 52-Week Range (€) | 2.14 - 8.45 | ||
| Shares Outstanding (Mil) | 9.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NRX Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NRX Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NRX Pharmaceuticals Inc Frequently Asked Questions
What is NRX Pharmaceuticals Inc(STU:B1Q)'s stock price today?
The current price of STU:B1Q is €4.88. The 52 week high of STU:B1Q is €8.45 and 52 week low is €2.14.
When is next earnings date of NRX Pharmaceuticals Inc(STU:B1Q)?
The next earnings date of NRX Pharmaceuticals Inc(STU:B1Q) is 2025-04-01 Est..
Does NRX Pharmaceuticals Inc(STU:B1Q) pay dividends? If so, how much?
NRX Pharmaceuticals Inc(STU:B1Q) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers